Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Board of Directors
    • Management Team
  • Investors & Media
  • Contact

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

By jgardnerJune 1, 2014Publications
Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

Adjuvance cofounders report the design, develop and adjuvant activity of novel, truncated QS-21 analogs.

Tejada_nchem.1963

Post navigation

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol

Recent Posts

  • ADJUVANCE PRESENTS ITS 2021 POTENTIAL AND PLANS AT THE BIOTECH SHOWCASE
  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
  • NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme